I find it difficult to accept without some evidence that a TMP gel somehow bends the risk benefit curve
But i just explained it to you south.
TPM can control rate of release and depth of penetration to either target the systemic system or in this case target superficial soft tissues, bypassing the systemic system, avoiding systemic adverse reactions.
boost for global diclofenac gel market, page-11
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $11.50K | 4.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 63 | 101422109 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 20872825 | 7 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |